Rhino Propels Federated AI into the Enterprise Tech Stack IQVIA Publishes its 2022 Environmental, Social and Governance Report
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG)…
Thales and LuxCarta sign a partnership to offer artificial intelligence powered solutions for military intelligence and cartography
Sophia Antipolis, France – February 23, 2023 – Thales and LuxCarta, a company specialized in…
Mount Graham Regional Medical Center selects HealthStore® to retire legacy systems & access historical patient data
WOBURN, MA – 23 February 2023 – Mount Graham Regional Medical Center (MGRMC), Arizona, has…
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which…
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Patent Application Published for PharmAla Biotech’s MDMA Analogs
Patent covers 6 novel compositions of matter, which PharmAla has been studying in preclinical testing…
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially…
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated,…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom…
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
Nes-Ziona, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) — Medigene AG (Medigene, FSE:…
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company…
Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
MORRISTOWN, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE)…
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models…
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline…
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a…